keyword
MENU ▼
Read by QxMD icon Read
search

Pityriasis rubra pilaris

keyword
https://www.readbyqxmd.com/read/29609014/biologics-for-pityriasis-rubra-pilaris-treatment-a-review-of-the-literature
#1
REVIEW
Monica Napolitano, Damiano Abeni, Biagio Didona
Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease, often refractory to conventional therapies. The off-label use of biologics, such as anti-TNF, -IL-12/IL-23, -IL-17 agents, has been proven successful, in the last two decades, in PRP treatment. Our aim was to analyse the literature for the use of biologics in PRP treatment. We conducted a review by "Pubmed" and "clinicaltrial.gov" searches. 68 articles met our selection criteria and were herein discussed. Out of 86 PRP patients, the vast majority of which treated with anti-TNF, -IL-12/IL-23, and -IL-17 biologics, either alone or in combination therapy, a marked-to-complete response (50-78%), a partial response (11-25%) or no/poor response (11-25%) was observed...
March 30, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29604103/recalcitrant-psoriasiform-dermatosis-of-the-face-is-it-related-to-pityriasis-rubra-pilaris
#2
Emily Yiping Gan, See Ket Ng, Chee Leok Goh, Siong See Joyce Lee
BACKGROUND: There are patients with recalcitrant psoriasiform plaques that do not fit into conventional categories of facial dermatoses. Our study aims to describe the clinico-pathological characteristics of several patients with a unique presentation of persistent psoriasiform facial rashes. METHODS: This retrospective cross-sectional study analyzed clinical and histological data of known cases of recalcitrant psoriasiform dermatosis of the face diagnosed at National Skin Centre, Singapore, over 10 years...
March 31, 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29518460/type-i-pityriasis-rubra-pilaris-treated-with-tumor-necrosis-factor-inhibitors-ustekinumab-or-secukinumab-a-systematic-review
#3
Nolan J Maloney, Lisa D Hisaw, Scott Worswick
No abstract text is available yet for this article.
March 5, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29477734/card14-associated-papulosquamous-eruption-a-spectrum-including-features-of-psoriasis-and-pityriasis-rubra-pilaris
#4
Brittany G Craiglow, Lynn M Boyden, Ronghua Hu, Marie Virtanen, John Su, Gabriela Rodriguez, Catherine McCarthy, Paula Luna, Margarita Larralde, Stephen Humphrey, Kristen E Holland, Marcia Hogeling, Benjamin Hidalgo-Matlock, Bruno Ferrari, Esteban Fernandez-Faith, Beth Drolet, Kelly M Cordoro, Anne M Bowcock, Richard J Antaya, Kurt Ashack, Richard J Ashack, Richard P Lifton, Leonard M Milstone, Amy S Paller, Keith A Choate
BACKGROUND: Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-α inhibitors. OBJECTIVE: We sought to describe the clinical characteristics, family history, and response to therapy in subjects with papulosquamous eruptions due to mutations in CARD14...
March 1, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29440245/pityriasis-rubra-pilaris-a-rare-inflammatory-dermatosis
#5
Aine Kelly, Aoife Lally
No abstract text is available yet for this article.
February 11, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29422292/autoinflammatory-keratinization-diseases-an-emerging-concept-encompassing-various-inflammatory-keratinization-disorders-of-the-skin
#6
Masashi Akiyama, Takuya Takeichi, John A McGrath, Kazumitsu Sugiura
Classifying inflammatory skin diseases is challenging, especially for the expanding group of disorders triggered by genetic factors resulting in hyperactivated innate immunity that result in overlapping patterns of dermal and epidermal inflammation with hyperkeratosis. For such conditions, the umbrella term "autoinflammatory keratinization diseases" (AIKD) has been proposed. AIKD encompasses diseases with mixed pathomechanisms of autoinflammation and autoimmunity, and includes IL-36 receptor antagonist (IL-36Ra)-related pustulosis, CARD14-mediated pustular psoriasis, pityriasis rubra pilaris (PRP) type V, and familial keratosis lichenoides chronica (KLC)...
February 1, 2018: Journal of Dermatological Science
https://www.readbyqxmd.com/read/29417801/rapid-response-to-cyclosporine-in-a-rare-case-of-pityriasis-rubra-pilaris-with-autoantibodies-and-systemic-symptoms
#7
Laura C Gironi, Rossana Tiberio, Lorenzo Dagna, Gianluca Landucci, Angela Giacalone, Renzo L Boldorini, Enrico Colombo, Paola Savoia
No abstract text is available yet for this article.
February 7, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29400288/a-case-of-severe-pityriasis-rubra-pilaris-with-a-dramatic-response-to-apremilast
#8
Lucie Pellonnet, Fanny Beltzung, Frédéric Franck, Jacques Rouanet, Michel D'incan
No abstract text is available yet for this article.
February 1, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29335741/methotrexate-treatment-for-pityriasis-rubra-pilaris-a-case-series-and-literature-review
#9
Lukas Koch, Clemens Schöffl, Werner Aberer, Cesare Massone
Treatment recommendations for pityriasis rubra pilaris (PRP) are based solely on case reports and small case series, as to-date no randomized controlled trials are available. We present here a case series of 3 patients and a literature review of 28 studies treating a total of 116 patients, with the aim of providing data regarding efficacy and safety of methotrexate in the treatment of PRP. Methotrexate was effective in our patients; the review showed an overall response rate of 65.5% with complete clearing in 23...
January 16, 2018: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29302927/a-review-on-pityriasis-rubra-pilaris
#10
REVIEW
Dingyuan Wang, Vanessa Cui-Lian Chong, Wei-Sheng Chong, Hazel H Oon
Pityriasis rubra pilaris (PRP) is an idiopathic, papulosquamous inflammatory dermatosis. It is characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques, islands of sparing, and palmoplantar keratoderma. PRP can be subdivided into six clinical subtypes according to Griffiths' classification, based on age of onset, disease extent, prognosis, and other associated features. The sixth subtype of PRP occurs in individuals affected by HIV infection, and retroviral screening in all de novo cases of PRP is advised...
January 4, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29290415/-pityriasis-rubra-pilaris
#11
S Quenan, E Laffitte
Pityriasis rubra pilaris is a rare heterogeneous dermatosis associating three clinical signs to different degrees: follicular corneal papules, reddish-orange palmoplantar keratoderma and erythematosquamous lesions that may in some cases be very extensive, interspersed with patches of healthy skin. The aetiology is unclear, and in most cases, the trigger factors consist of trauma or infection, probably in subjects with an existing predisposition. In other cases, the condition is associated with immunological disorders or, in familial cases, genetic keratinisation abnormalities similar to ichthyosis...
January 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29247481/pityriasis-rubra-pilaris-algorithms-for-diagnosis-and-treatment
#12
REVIEW
S Roenneberg, T Biedermann
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages and also children. The clinical appearance of PRP is highly variable, as is the individual prognosis. Therefore, stratifying PRP into six disease subtypes represents a first step to personalized medicine for this rare inflammatory skin disease. The next step should be to associate specific therapeutic strategies with these subtypes of PRP. However, no randomized, controlled trials on the treatment of PRP have been performed...
December 15, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29184428/management-of-refractory-pityriasis-rubra-pilaris-challenges-and-solutions
#13
REVIEW
Gaia Moretta, Erika V De Luca, Alessandro Di Stefani
Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory papulosquamous skin disease. Its clinical presentation and evolution is very variable. The most frequent clinical features are follicular papules, progressing to yellow-orange erythroderma with round small areas of normal skin and the well-demarcated palmoplantar keratoderma. Actually, six different types of PRP have been described based on clinical characteristics, age of onset, and prognosis. The pathogenesis is still unknown, and treatment can be challenging...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/29138996/ichthyosiform-pityriasis-rubra-pilaris-like-eruption-secondary-to-ponatinib-therapy-case-report-and-literature-review
#14
Ariel E Eber, Alyx Rosen, Kate E Oberlin, Alessio Giubellino, Paolo Romanelli
Tyrosine kinase inhibitors have revolutionized the chemotherapy arena as targeted therapies for a multitude of malignancies. They are more selective than conventional chemotherapy, and often elicit fewer systemic adverse events, however toxicities still exist. Cutaneous toxicities are common and their management presents a novel challenge to physicians and patients. Ponatinib is a third-generation tyrosine kinase inhibitor increasingly reported to cause cutaneous eruption. A 50-year-old woman with a history of chronic myelogenous leukemia presented with a 4-month history of worsening atrophic and ichthyosiform pink plaques involving the axillae, thighs and abdomen; red patches were also observed on the cheeks and forehead...
November 14, 2017: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/29121136/pityriasis-rubra-pilaris-and-severe-hypereosinophilia
#15
Lulit Price, Erin Lesesky
No abstract text is available yet for this article.
September 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/29080273/ustekinumab-treatment-of-pityriasis-rubra-pilaris-a-report-of-five-cases
#16
Monica Napolitano, Luigi Lembo, Luca Fania, Damiano Abeni, Dario Didona, Biagio Didona
Pityriasis rubra pilaris (PRP) is a rare, chronic, inflammatory skin disease of unknown etiology. Patients refractory to conventional therapies have been treated successfully with biologic drugs such as anti-tumor necrosis factor agents. Recently, a role of the interleukin-23/T-helper 17 axis in PRP has been described. Our objective was to assess the effectiveness of ustekinumab in five patients with adult-onset PRP refractory to conventional therapies. In the present study, four patients had type I and one patient type II adult-onset PRP...
October 28, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29072324/juvenile-pityriasis-rubra-pilaris-successful-treatment-with-methotrexate
#17
A Alazemi, G Balakirski, F AlShehhi, S Lehmann, K Tenbrock, M Megahed
No abstract text is available yet for this article.
January 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29044698/methotrexate-treatment-in-a-case-of-juvenile-pityriasis-rubra-pilaris
#18
Anne H Boyd, Ingrid C Polcari
An 8-year-old boy who was initially diagnosed with plaque psoriasis failed management with topical therapies and skin biopsy confirmed the suspected diagnosis of juvenile pityriasis rubra pilaris (PRP). Pityriasis rubra pilaris is a rare inflammatory disorder of the skin characterized by follicular keratotic papules coalescing into plaques, along with palmoplantar keratoderma. Treatment modalities include topical and systemic therapies, although previous studies have not shown much benefit with methotrexate in children...
January 2018: Pediatric Dermatology
https://www.readbyqxmd.com/read/29034547/refractory-pityriasis-rubra-pilaris-treated-with-etanercept-adalimumab-or-ustekinumab-a-retrospective-investigation
#19
Nolan J Maloney, Lisa D Hisaw, Scott Worswick
Pityriasis rubra pilaris (PRP) is a rare, difficult to treat papulosquamous disorder that responds variably to retinoids and immunosuppression. Successful use of biologics for treating PRP has been described in the literature by case reports and a limited number of case series. To provide additional data, we retrospectively analyzed cases of PRP treated with biologics at our institution. We identified seven patients with a clear diagnosis of PRP treated with adalimumab, etanercept, and/or ustekinumab at our institution from January 1, 2014 to April 1, 2017...
November 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28776328/acute-generalized-exanthematous-pustulosis-and-polyarthritis-associated-with-a-novel-card14-mutation
#20
Sebastian Podlipnik, Raul Castellanos-Moreira, Helena Florez-Enrich, Juan Ignacio Arostegui, José Manuel Mascaró
Acute generalised exanthematous pustulosis (AGEP) is a rare toxicoderma characterised by an acute onset rash, with many sterile pustules on the surface, high fever and increased acute phase reactants. We report the case of a patient who presented to the dermatology department with an AGEP and polyarthritis, in which a novel CARD14 mutation was identified. The pathophysiological mechanism of AGEP remains unclear, although mutations in the IL36RN gene have been identified in a small subset of AGEP patients. Similarly, mutations in the CARD14 gene have been linked to pustular types of psoriasis and familiar cases of pityriasis rubra pilaris; however, there are no reports associating mutations in the CARD14 gene with AGEP...
February 2018: Australasian Journal of Dermatology
keyword
keyword
57683
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"